{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:34:41Z","timestamp":1782516881014,"version":"3.54.5"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Anna and Andr\u00e9 Livio Glauser","award":["2020-02"],"award-info":[{"award-number":["2020-02"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Human Papillomaviruses (HPV) are highly prevalent in the sexually active populations, with a significant burden in terms of health and psychological cost in all class ages. High-risk (HR) HPV genotypes are associated with anogenital dysplasia and cancers, and anal HPV-induced cancer is increasingly observed in women. The interactions of HPV genotype\u2019s between the anus and the cervix, and the subsequent occurrence of dysplasia remains unclear. This clinical study set out to test the hypothesis that risk factors for anal HR-HPV and dysplasia may differ in women with or without cervical dysplasia or in HIV-positive women.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Cervical and anal HPV genotypes and cytology testing will be performed prospectively in a cohort of women recruited in a tertiary university hospital in Switzerland. Women will be allocated to three groups: 1) normal previous cervical smear; 2) high-grade cervical dysplasia (H-SIL) at previous cervical smear; 3) HIV+, independently of previous cervical smear result. General inclusion criteria comprised the followings: Female\u2014Age &gt; = 18 years; Satisfactory understanding of French; No objection to HIV testing. Specific inclusion criteria are: Group 1, no past or current gynecological dysplasia and HIV negative; Group 2, Gynecological dysplasia (H-SIL) or carcinoma in situ demonstrated by histology (vulvar, vaginal or cervical) and HIV negative; Group 3: HIV-positive (regardless of viremia or CD4 count) with or without gynecological dysplasia. General exclusion criteria are: Pregnancy; History of anal dysplasia\/cancer; Status after pelvic radiotherapy; Absence of anus and anal canal. Estimated prevalences of anal dysplasia are: in group 1, 1% (0\u20132%); in group 2, 15% (5\u201327%), and in group 3, 30% (19\u201345%). With a 10% margin error, a sample size of 120 women per group is required to reach 90% power for detecting statistical significance (unilateral \u03b1 error of 5%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Discussion<\/jats:title>\n<jats:p>The primary endpoint is the prevalence of anal and cervical dysplasia, and description of the respective HPV genotypes in each group. The results of this study could improve the standard of screening of cervical and anal dysplasia in women through evidence of concomitant presence of HPV\u2019s and\/or dysplasia in anus or cervix to support vaccination for instance. Beginning of recruitment started in September 2016. Results should be presented in end of 2022. Preliminary analysis for first 100 patients reveals that the mean age of the population is 39.6 (\u00b1 10.9) years with mean age of first sexual intercourse of 18.5 (\u00b1 3.9) years. In this cohort, 12% are vaccinated and 38% having had anal intercourse. Overall, 43% of the studied population had cervical HR-HPV in the studied population, and 53% had normal cytology. Anal LR HPV and HR HP were found in 27.6% and 38.4% of all patients respectively. Eighty percent had normal anal cytology. Groups 1,2 and 3 had a significant difference in terms of age, gestity, parity, age of first sexual intercourse, systematic use of condom, number of cervical LR HPV and HR HPV and abnormal cervical cytologies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The study was approved by the institutional review board\u2014<jats:bold>CER-VD#2015\u201300200<\/jats:bold>\u2014on the 29<jats:sup>th<\/jats:sup> of June 2016 and is registered on the Swiss National Clinical Trials Portal (SNCTP), <jats:bold>SNCTP000002567<\/jats:bold>, Registered 29 June 2016, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.kofam.ch\/en\/snctp-portal\/study\/40742\/\" xlink:type=\"simple\">https:\/\/www.kofam.ch\/en\/snctp-portal\/study\/40742\/<\/jats:ext-link><\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0276438","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T17:30:55Z","timestamp":1666373455000},"page":"e0276438","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of anal dysplasia and HPV genotypes in gynecology patients: The ANGY cross-sectional prospective clinical study protocol"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-7345","authenticated-orcid":true,"given":"Basile","family":"Pache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Balaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-1142","authenticated-orcid":true,"given":"Roland","family":"Sahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sempoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Mathevet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Jacot-Guillarmod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"Suppl 3","key":"pone.0276438.ref001","first-page":"S3\/11","article-title":"Chapter 2: The burden of HPV-related cancers","volume":"24","author":"DM Parkin","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"pone.0276438.ref002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00384-011-1298-1","article-title":"HPV and precancerous lesions of anal canal in women: systematic review.","volume":"27","author":"M Castor","year":"2012","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"pone.0276438.ref003","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study","volume":"129","author":"L Abramowitz","year":"2011","journal-title":"International journal of cancer"},{"issue":"4","key":"pone.0276438.ref004","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","article-title":"Carcinogenicity of human papillomaviruses","volume":"6","author":"V Cogliano","year":"2005","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0276438.ref005","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"H De Vuyst","year":"2009","journal-title":"International journal of cancer"},{"issue":"3","key":"pone.0276438.ref006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ajog.2015.03.034","article-title":"Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review.","volume":"213","author":"EA Stier","year":"2015","journal-title":"American journal of obstetrics and gynecology"},{"issue":"1","key":"pone.0276438.ref007","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/infdis\/jiq021","article-title":"Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study.","volume":"203","author":"AG Nyitray","year":"2011","journal-title":"The Journal of infectious diseases"},{"issue":"3","key":"pone.0276438.ref008","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ygyno.2009.05.008","article-title":"Anal human papillomavirus infection and abnormal anal cytology in women with genital neoplasia","volume":"114","author":"IU Park","year":"2009","journal-title":"Gynecol Oncol"},{"key":"pone.0276438.ref009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/1471-2407-11-473","article-title":"High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology","volume":"11","author":"R Crawford","year":"2011","journal-title":"BMC Cancer"},{"issue":"1","key":"pone.0276438.ref010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-6413-1-4","article-title":"Second edition of \u2019The Bethesda System for reporting cervical cytology\u2019\u2014atlas, website, and Bethesda interobserver reproducibility project.","volume":"1","author":"R Nayar","year":"2004","journal-title":"Cytojournal"},{"issue":"1","key":"pone.0276438.ref011","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/s12879-017-2867-x","article-title":"Impact of HPV vaccination with Gardasil(R) in Switzerland.","volume":"17","author":"M Jacot-Guillarmod","year":"2017","journal-title":"BMC infectious diseases."},{"issue":"1","key":"pone.0276438.ref012","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/AOG.0b013e318254f90c","article-title":"2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy","volume":"120","author":"J Bornstein","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"10","key":"pone.0276438.ref013","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.5858\/arpa.LGT200570","article-title":"The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"136","author":"TM Darragh","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"pone.0276438.ref014","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/DCR.0b013e318255815e","article-title":"Practice parameters for anal squamous neoplasms","volume":"55","author":"SR Steele","year":"2012","journal-title":"Dis Colon Rectum"},{"issue":"611","key":"pone.0276438.ref015","first-page":"1230","article-title":"[Screening for anal cancer: is it the same as for cervical cancer?].","volume":"14","author":"C Duvoisin Cordoba","year":"2018","journal-title":"Rev Med Suisse."},{"issue":"11 Pt 1","key":"pone.0276438.ref016","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1158\/1055-9965.EPI-05-0460","article-title":"Anal human papillomavirus infection in women and its relationship with cervical infection","volume":"14","author":"BY Hernandez","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"pone.0276438.ref017","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/OLQ.0b013e3181f70253","article-title":"Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV\/AIDS in the era of effective therapy (the SUN study).","volume":"38","author":"EM Kojic","year":"2011","journal-title":"Sex Transm Dis."},{"issue":"7","key":"pone.0276438.ref018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/infdis\/jis458","article-title":"Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in costa rica","volume":"206","author":"FA Castro","year":"2012","journal-title":"Journal of Infectious Diseases"},{"issue":"1","key":"pone.0276438.ref019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cncy.20126","article-title":"Anal cancer and cervical cancer screening: key differences","volume":"119","author":"TM Darragh","year":"2011","journal-title":"Cancer Cytopathol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T17:31:24Z","timestamp":1666373484000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276438"}},"subtitle":[],"editor":[{"given":"Kazunori","family":"Nagasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0276438","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]}}}